Trials / Completed
CompletedNCT00799877
Chronic Plaque Psoriasis (Ps) Registry
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6,065 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
Detailed description
ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry.
Conditions
Timeline
- Start date
- 2008-09-26
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
- First posted
- 2008-12-01
- Last updated
- 2024-03-15
Locations
339 sites across 14 countries: United States, Austria, Canada, Czechia, Denmark, France, Germany, Greece, Ireland, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00799877. Inclusion in this directory is not an endorsement.